Breast Cancer, Sexuality and Black Cohosh

NCT ID: NCT02467686

Last Updated: 2017-03-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen or aromatase inhibitor through questionnaires.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

For the study will be recruited 60 women treated with breast cancer, using tamoxifen or aromatase inhibitor, are in menopause, hot flashes and has with or without sexual life. They will answer the questionnaires: Kupperman, World Health Organization Quality of Life (WHOQOL) and those sexually active will have Female Sexual Function Index (FSFI). The control group will have 30 patients using tamoxifen alone or inhibitor. The other group will have 30 patients receiving tamoxifen or inhibitor and will start with 2 tablets per day of dry extract of Cimicifuga racemosa. They will be followed for 6 months and answer questionnaires at the first visit, 3-month and 6-month follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sexuality

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cimicifuga racemosa

The other group will have 30 patients receiving tamoxifen 20 mg orally daily or exemestane (aromatase inhibitor) 25 mg orally once daily after a meal and will start with 2 tablets per day of dry extract of Cimicifuga racemosa.

Each tablet contains 20 mg of dry extract of Cimicifuga racemosa standardized between 1 mg and 1.25 mg of triterpene glycosides expressed in 26-deoxyactein. Will be guided 1 tablet 12/12 hours for 6 months.

WHOQOL questionnaire (The World Health Organization Quality of life)application for evaluation at the first visit, 3-month and 6-month follow-up.

FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.

Group Type ACTIVE_COMPARATOR

WHOQOL questionnaire

Intervention Type BEHAVIORAL

WHO defines Quality of Life as individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.

FSFI questionnaire

Intervention Type BEHAVIORAL

FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.

kupperman scale

Intervention Type BEHAVIORAL

Kupperman scale is a tool to help evaluate the severity of menopausal symptoms

Cimicifuga racemosa

Intervention Type DRUG

The Cimicifuga racemosa effects on the sexuality of women with Breast cancer

tamoxifen

Intervention Type DRUG

The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen

exemestane

Intervention Type DRUG

The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using aromatase inhibitor.

Control

Control group will have 30 patients receiving tamoxifen 20 mg orally daily or exemestane (aromatase inhibitor) 25 mg orally once daily after a meal . They will be followed for 6 months and answer Kupperman scale, WHOQOL questionnaire and FSFI questionnaire at the first visit, 3-month and 6-month follow-up.

WHOQOL questionnaire (The World Health Organization Quality of life)application for evaluation at the first visit, 3-month and 6-month follow-up.

FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.

Group Type PLACEBO_COMPARATOR

WHOQOL questionnaire

Intervention Type BEHAVIORAL

WHO defines Quality of Life as individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.

FSFI questionnaire

Intervention Type BEHAVIORAL

FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.

kupperman scale

Intervention Type BEHAVIORAL

Kupperman scale is a tool to help evaluate the severity of menopausal symptoms

tamoxifen

Intervention Type DRUG

The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen

exemestane

Intervention Type DRUG

The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using aromatase inhibitor.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

WHOQOL questionnaire

WHO defines Quality of Life as individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.

Intervention Type BEHAVIORAL

FSFI questionnaire

FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.

Intervention Type BEHAVIORAL

kupperman scale

Kupperman scale is a tool to help evaluate the severity of menopausal symptoms

Intervention Type BEHAVIORAL

Cimicifuga racemosa

The Cimicifuga racemosa effects on the sexuality of women with Breast cancer

Intervention Type DRUG

tamoxifen

The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen

Intervention Type DRUG

exemestane

The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using aromatase inhibitor.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

The World Health Organization Quality of Life Female sexual function index (FSFI) questionnaire Blatt-Kupperman menopausal index Black Cohosh aromatase inhibitor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Menopausal women with breast cancer treated and using tamoxifen or aromatase inhibitor.
* With hot flashes and with or without active sexual life.

Exclusion Criteria

* Women did not have breast cancer
* do not use tamoxifen or aromatase inhibitor
* not in menopause and not have hot flashes
Minimum Eligible Age

48 Years

Maximum Eligible Age

68 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Irmandade da Santa Casa de Misericordia de Sao Paulo

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Carolina Furtado Macruz

Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Black cohosh

Role: PRINCIPAL_INVESTIGATOR

Irmandade da Santa Casa Misericordia Sao Paulo

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Carolina Furtado Macruz

São Paulo, São Paulo, Brazil

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Carolina Macruz

Role: CONTACT

+5511999141447

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Carolina Macruz

Role: primary

+5511999141447

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

349441

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.